» Articles » PMID: 12724217

Sensitive Detection of DNA Methylation

Overview
Specialty Science
Date 2003 May 2
PMID 12724217
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

In recent years, many molecular biomarkers have been discovered that are capable of distinguishing tumors from normal tissue. Among the different types of markers, DNA methylation markers stand out for their potential to provide a unique combination of specificity, sensitivity, high information content, and applicability to a wide variety of clinical specimens. Methylation markers are particularly suited for situations where sensitive detection is necessary, such as when tumor DNA is either scarce or diluted by excess normal DNA. One of the most widely used methods for measuring methylation levels, methylation-specific PCR (MSP), has been proved to be a very effective tool in situations requiring sensitive detection. The addition of fluorogenic probes makes these assays more informative, quantitative, and suitable for a clinical format. The field of sensitive detection is not limited to MSP; hence, an alternative methylation-sensitive amplification is discussed. PCR-based methylation assays have been applied to the detection of tumor DNA in a variety of body fluids, including serum, plasma, urine, sputum, and lavage fluids. In many cases, the sensitivity and specificity of these detection assays has been impressive, but important technological issues remain in areas such as sample preparation, assay design, and marker selection. Once these technical concerns have been addressed, the sensitive detection of methylation will provide a powerful diagnostic and prognostic tool, especially for the early detection of preneoplastic and neoplastic lesions.

Citing Articles

Decoding the Epigenetics of Infertility: Mechanisms, Environmental Influences, and Therapeutic Strategies.

Saftic Martinovic L, Mladenic T, Lovric D, Ostojic S, Devic Pavlic S Epigenomes. 2024; 8(3).

PMID: 39311136 PMC: 11417785. DOI: 10.3390/epigenomes8030034.


Epigenetic Therapies and Biomarkers in Breast Cancer.

Brown L, Achinger-Kawecka J, Portman N, Clark S, Stirzaker C, Lim E Cancers (Basel). 2022; 14(3).

PMID: 35158742 PMC: 8833457. DOI: 10.3390/cancers14030474.


Comprehensive evaluation of targeted multiplex bisulphite PCR sequencing for validation of DNA methylation biomarker panels.

Lam D, Luu P, Song J, Qu W, Risbridger G, Lawrence M Clin Epigenetics. 2020; 12(1):90.

PMID: 32571390 PMC: 7310104. DOI: 10.1186/s13148-020-00880-y.


A rapid and accurate methylation-sensitive high-resolution melting analysis assay for the diagnosis of Prader Willi and Angelman patients.

Ferreira I, Dos Santos Cunha W, Gomes L, Cintra H, Lopes Cabral Guimaraes Fonseca L, Bastos E Mol Genet Genomic Med. 2019; 7(6):e637.

PMID: 31033246 PMC: 6565559. DOI: 10.1002/mgg3.637.


Testis specific Y-like 5: gene expression, methylation and implications for drug sensitivity in prostate carcinoma.

Kumar S, Bryan J, Esebua M, Amos-Landgraf J, May T BMC Cancer. 2017; 17(1):158.

PMID: 28235398 PMC: 5326500. DOI: 10.1186/s12885-017-3134-7.